Drug ads must now show you the price—a rare win for patient transparency
S. 229 — DTC Act of 2025 · Filed by Richard Durbin (D-IL) · 9 cosponsors · Introduced Jan 23, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill requires pharmaceutical companies to disclose pricing information in direct-to-consumer drug advertisements. When a drug ad appears on TV, radio, or online, it must now include the drug's price or a clear statement about where consumers can find pricing. The bill aims to help patients make informed decisions and reduce unnecessary prescriptions for expensive drugs by showing them upfront what medications actually cost.
Why we flagged it
The bill's core mechanism is a straightforward disclosure requirement—pharmaceutical advertisers must include pricing information in direct-to-consumer ads. This is a transparency measure, not a price-control or subsidy mechanism.
What the text implies
- Pharmaceutical companies may respond by reducing direct-to-consumer advertising volume, which could reduce patient awareness of treatment options but also reduce demand-inflation for expensive drugs.
- The bill does not define 'appropriate disclosure' in detail, leaving room for regulatory interpretation about what constitutes adequate pricing transparency (e.g., list price vs. net price vs. out-of-pocket cost).
The full analysis lists 4 implications of this text.
Who it affects
Ordinary citizens gain transparency about drug prices at the point of advertising, enabling more informed conversations with doctors and reducing the likelihood of requesting expensive drugs without understanding cost. The bill does not restrict access to medications or impose new costs on patients—it simply requires disclosure of information already known to manufacturers.